Entrar/Registro  
INICIO ENGLISH
 
Gaceta Médica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Gaceta Médica de México >Año 2013, No. 5


Fragoso LJM, Sierra MM, Vargas AG, Barrios RA, Ramírez BJ
El factor de necrosis tumoral α (TNF-α) en las enfermedades cardiovasculares: biología molecular y genética
Gac Med Mex 2013; 149 (5)

Idioma: Español
Referencias bibliográficas: 95
Paginas: 521-530
Archivo PDF: 231.71 Kb.


Texto completo




RESUMEN

Las enfermedades cardiovasculares representan la primera causa de morbimortalidad en el mundo y la principal problemática de salud pública a nivel global. En 1997, este grupo de enfermedades causó el 41% de las muertes en EE.UU. Se ha reportado que cerca de 60 millones de personas que viven en EE.UU. tienen algún tipo de enfermedad cardiovascular. Estas entidades son condiciones crónicas iniciadas por la desregulación en la respuesta inmunológica. El gen TNF-α y su producto proteico: la citocina multifuncional TNF-α, juegan un papel determinante en el inicio, desarrollo, susceptibilidad, gravedad y respuesta al tratamiento, etc., en la enfermedad arterial coronaria (EAC). Esta revisión se enfoca en presentar al lector el rol biológico del TNF-α en el inicio y progresión de la disfunción endotelial, aterosclerosis y ruptura de la placa aterosclerótica, y cómo la variabilidad genética del TNF-α se relaciona con la susceptibilidad, la gravedad y la respuesta al tratamiento en la EAC, el infarto agudo de miocardio (IAM) con y sin elevación del segmento ST, la angina inestable (AI) y la reestenosis coronaria.


Palabras clave: EAC, TNF, Inflamación, Placas ateroscleróticas.


REFERENCIAS

  1. Braunwald E, Animan EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction –2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unestable Angina). Circulation. 2002;106:1893-900.

  2. Linde A, Mosier D, Blecha F, Melgarejo T. Innate immunity and inflammation- New frontiers in comparative cardiovascular pathology. Cardiovascular Res. 2007;73:26-36.

  3. Nathan C. Epidemic inflammation: pondering obesity. Mol Med. 2008; 14:485-92.

  4. Fragoso-Lona JM, Ramírez Bello J, Cruz-Robles D, Pérez-Méndez O, de la Peña A, Vargas-Alarcón G. Pro-inflammatory and anti-inflammatory markers in coronary artery disease and acute isquemic coronary syndrome. Arch Cardiol Mex. 2009;79:54-62.

  5. Scrivo R, Vasile M, Bartosiewicz I, Valesini G. Inflammation as «common soil» of the multifactorial diseases. Autoimmun Rev. 2011;10:369-74.

  6. Bultink IE, Vis M, van der Horst-Bruinsma IE, Lems WF. Inflammatory rheumatoid disorders and bone. Curr Rheumatol Rep. 2012;14:224-30.

  7. McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol. 2009;6:410-7.

  8. Zhang H, Park Y, Wu J, et al. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond). 2009;116:219-30.

  9. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651-65.

  10. Nedwin GE, Naylor SL, Sakaguchi AY, et al. Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal locatization. Nucleic Acids Res. 1985;13:6361-73.

  11. Wang Q. Advances in the genetic basis of coronary artery disease. Curr Atheroscler Rep. 2005;7:235-41.

  12. Zintzaras E, Kitsios G, Kent D, et al. Genome-wide scan meta-analysis for pulse pressure. Hypertension. 2007;50:557-64.

  13. Holliday EG, Maguire JM, Evans TJ, et al. Common variants at 6p21.1 are associated with large artery atherosclerotic stroke. Nat Genet. 2012;44:1147-51.

  14. [Internet] Disponible en: http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?chooseRs=all&go=Go&locusId=7124

  15. Ramírez-Bello J, Vargas-Alarcón G, Tovilla Zárate C, Fragoso JM. Implicaciones funcionales de los polimorfismos de un sólo nucleótido-reguladores (rSNPs) y RNA estructurales (srSNPs) en enfermedades complejas. Gac Med Mex. 2013;2:220-8.

  16. Sadee W, Wang D, Papp AC, Pinsonneault JK, et al. Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clin Pharmacol Ther. 2011;89:355-65.

  17. Ramírez Bello J, Pérez Méndez O, Ramírez Fuentes S, Carrillo Sánchez S, Vargas Alarcón G, Fragoso JM. Genetic and genomic studies in the hipertensión: an actualization of the genomic studies. Arch Cardiol Mex. 2011;81:240-50.

  18. Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter promoter polymorphism in TNF alpha gene regulation. J Inflamm. 1995- 1996;46:32-41.

  19. Hohioh H, Tokunaga K. Allele-specific binding of the ubiquitous transcription factor OCT-1 to the functional single nucleotide polymorphism (SNP) sites in the tumor necrosis factor alpha gene (TNFA) promoter. Genes Immun. 2001;2:105-9.

  20. Knight JC, Udalova I, Hill AV, et al. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet. 1999;22:145-50.

  21. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94:3195-9.

  22. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49:1215-28.

  23. Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol. 2010;45:146-69.

  24. Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryo Gene Expr. 2010;20:87-103.

  25. Thomas PS. Tumor necrosis factor-alpha: the role of this multifactorial cytokine in asthma. Immunol Cell Biol. 2001;79:132-40.

  26. McKellar GE, McCarey DW, Sattar N, McInnes IB. Roles for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol. 2009;6:410-7.

  27. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45-65.

  28. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296: 1634-5.

  29. MacNaul KL, Hutchinson NI. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endethelial cells under normal and inflammatory conditions. Biochem Biophys Res Commun. 1993;196:1330-4.

  30. Goodwin BL, Pendleton LC, Levy MM, Solomonson LP, Eichler DC. Tumor necrosis factor-alpha reduces arginosuccinate systhase expression and nitric oxide production in aortic endothelial cells. Am J Physiol Heart Cir Physiol. 2007;293:H1115-21.

  31. Seidel M, Billert H, Kurpisz M. Regulation of eNOS expression in HCAEC cell line treated with opioids and proinflammatory cytokines. Kardiol Pol. 2006;64:153-8.

  32. Picchi A, Gao X, Belmadani S, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res. 2006;99:69-77.

  33. Martens FM, Rabelink TJ, op´tRoodt J, de Koning EJ, Visseren FL. TNFalpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J. 2006;27:1605-9.

  34. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol. 2000;20:E83-8.

  35. Shi GP. Immunomodulation of vascular diseases: atherosclerosis and autoimmunity. Eur J Vasc Endovasc Surg. 2010;39:485-94.

  36. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Ann Rev Immunol. 2009;27:165-97.

  37. Surmi BK, Hasty AH. The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue. Vasc Pharmacol. 2010;52; 27-36.

  38. Zernecke A, Weber C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res. 2010;86:192-201.

  39. Jovinge S, Hamsten A, Tornvall P, et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. 1998;47:113-8.

  40. Vargas Alarcón G, Martínez Ríos MA, Peña Duque MA, et al. The MHC- 2TA 1614 C>G polymorphism is associated with risk of developing acute coronary syndrome. Mol Immunol. 2013;55:424-8.

  41. Delgadillo H, Vargas Alarcón G, Gómez Monterrosas O, et al. The MHC2TA gene polymorphisms are not associated with restenosis alter coronary stenting in Mexican patients. Arch Cardiol Mex. 2012; 82:208-13.

  42. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410-22.

  43. Kleinbongard P, Heusch G, Schulz R. TNF alpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther. 2010;127:295-314.

  44. Gotsman I, Stabholz A, Planer D, et al. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? Isr Med Assoc J. 2008;10:494-8.

  45. Zhou Y, Wei Y, Wang L, et al. Decreased adiponectin and increased inflammation expression in epicardial adipose tissue in coronary artery disease. Cardiovasc Diabetol. 2011;10:2.

  46. Cho HC, Yu G, Lee MY, Kim HS, Shin DH, Kim YN. TNF-α polymorphisms and coronary artery disease: association study in the Korean population. Ctokine. 2013;62:104-9.

  47. Giacconi R, Cipriano C, Muti E, et al. Involvement of -308 TNF-alpha and 1267 Hsp70-2 polymorphisms and zinc status in the susceptibility of coronary artery disease (CAD) in old patients. Biogerontology. 2006;7:347-56.

  48. Luo JG. Relationship between serum IL-8 hsCRP, TNF-α and coronary lesions in CHD patients. Bao Yu Fen Zi Mian Yi Xue Za Zhi Xi. 2010;26:789-91.

  49. Morange PE, Tregouet DA, Godefroy T, et al. Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study. J Mol Med (Berl). 2008;86:1153-61.

  50. Safranow K, Dziedziejko V, Rzeuski R, et al. Plasma concentrations of TNF-alpha and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease. Tissue Antigens. 2009;74:386-92.

  51. Sbarsi I, Falcone C, Boiocchi C, et al. Inflammation and atherosclerosis: the role of TNF and TNF receptors polymorphisms in coronary artery disease. Int J Immunopathol Pharmacol. 2007;20:145-54.

  52. Sobti RC, Kler R, Sharma YP, Talwar KK, Singh N. Risk of obesity and type 2 diabetes with tumor necrosis factor-α 308G/A gene polymorphism in metabolic syndrome and coronary artery disease subjects. Mol Cell Biochem. 2012;360:1-7.

  53. Ghazouani L, Ben Hadj Khalifa S, Abboud N, et al. TNF-alpha -308G>A and IL-6 -174G>C polymorphisms in Tunisian patients with coronary artery disease. Clin Biochem. 2010;43:1085-9.

  54. Ghazouani L, Khalifa SB, Abboud N, et al. -308G>A and -1031T>C tumor necrosis factor gene polymorphisms in Tunisian patients with coronary artery disease. Clin Chem Lab Med. 2009;47:1247-51.

  55. Hou L, Huang J, Lu X, Wang L, Fan Z, Gu D. Polymorphisms of tumor necrosis factor alpha gene and coronary heart disease in a Chinese Han population: interaction with cigarette smoking. Thromb Res. 2009;123:822-6.

  56. Zhang HF, Xie SL, Wang JF, Chen YX, Wang Y, Huang TC. Tumor necrosis factor-alpha G-308A gene polymorphism and coronary heart disease susceptibility: an update meta-analysis. Thromb Res. 2011;127:400-5.

  57. Chu H, Yang J, Mi S, et al. Tumor necrosis factor-alpha G-308 A polymorphis and risk of coronary Herat disease and myocardial infarction: A case-control study and meta-analysis. J Cardiovasc Dis Res. 2012;3:84-90.

  58. Vargas Alarcón G, Fragoso JM, Delgadillo H. Acute coronary syndrome. Physiopathology and genetics. Rev Invest Clin. 2011;63:64-74.

  59. Schulz R, Heusch G. Tumor necrosis factor-alpha and its receptors 1 qnd 2: Yin and Yang in myicardial infarction? Circulation. 2009;119: 1355-7.

  60. Schulz R, Aker S, Belosjorow S, Heusch G. TNFalpha in ischemia/reperfusion injury and Herat failure. Basic Res Cardiol. 2004;99:8-11.

  61. Gonzálvez M, Ruiz Ros JA, Pérez Paredes M, et al. Prognostic value of tumor necrosis factor-alpha in patients with ST-segment elevation acute myocardial infarction. Rev Esp Cardiol. 2007;60:1233-41.

  62. Anfossi G, Russo I, Doronzo G, Pomero A, Trovati M. Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators Inflamm. 2010;2010:174341.

  63. Mielczarek-Palacz A, Sikora J, Kondera-Anasz Z, Smcz M. Changes in concentrations of tumor necrosis factor TNF and its soluble receptor type 1 (sTNF-r1) and type 2 (sTNFR-R2) in serum of patients with ST-segment elevation myocardial infarction. Wiad Lek. 2011;64:71-4.

  64. Kehmeier ES, Lepper W, Kropp M, et al. TNF-α, myocardial perfusion and function in patients with ST-segment elevation myocardial infarction and primary percutaneous coronary intervention. Clin Res Cardiol. 2012;101:815-27.

  65. Correia LC, Andrade BB, Borges VM, et al. Prognostic value of cytokines and chemokines in addition to the GRACE Score in non-ST-elevation acute coronary syndromes. Clin Chim Acta. 2010;411:540-5.

  66. Ozeren A, Aydin M, Tokac M, et al. Levels of srum IL-1beta, IL-2, IL-8 and tumor necrosis factor-alpha in patients with unstable angina pectoris. Mediators Inflamm. 2003;12:361-5.

  67. Koch W, Kastrati A, Böttiger C, Mehilli J, von Beckerath N, Schömig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis. 2001;159:137-44.

  68. Antonicelli R, Olivieri F, Cavallone L, et al. Tumor necrosis factor-alpha gene -308G>A polymorphism is associated with ST-elevation myocardial infarction and with high plasma levels of biochemical ischemia markers. Coron Artery Dis. 2005;16:489-93.

  69. Chang WT, Wang YC, Chen CC, et al. The -308G/A of tumor necrosis factor (TNF)-α and 825C/T of guanidine Nucleotide Binding Protein 3 (GNB3) are associated with onset of acute myocardial infarction and obesity in Taiwan. Int J Mol Sci. 2012;13:1846-57.

  70. Vaccarino L, Vitale S, Caruso M, et al. Myocardial infarction marker levels are influenced by prothrombin and tumor necrosis factor-α gene polymorphisms in young patients. Cytokine. 2013;61:218-22.

  71. Zeybek U, Toptas B, Karaali ZE, Kendir M, Cakmakoglu B. Effect of TNF-α and IL-1β genetic variants on the development of myocardial infarction in Turkish population. Mol Biol Rep. 2011;38:5453-7.

  72. Ghaderian SM, Akbarzadeh Najar R, Tabatabaei Panah AS. Tumor necrosis factor-α: investigationof gene polymorphism and regulation of TACE-TNF-α system in patients with acute myocardial infarction. Mol Biol Re. 2011;38:4971-7.

  73. Shevchenko AV, Golovanova OV, Konenkov VI, et al. Analysis of polymorphism of three positions of promoter region of TNF-gene in patients with ischemic heart disease, unstable angina and myiocardial infarction. Kardiologiia. 2010;50:9-14.

  74. Bernard V, Pillois X, Dubus I, et al. The -308G/A tumor necrosis factoralpha gene dimorphism: a risk factor for unstable angina. Clin Chem Lab Med. 2003;41:511-6.

  75. Liu Y, Jin W, Lu L, Chen QJ, Shen WF. Association between the -1031T/ C polymorphism in tumor necrosis factor-alpha gene and unstable angina. Zhonghua Yi Xue Yi Xue Za Zhi. 2009;26:571-4.

  76. King SB 3rd. Applying drug-eluting stents in clinical practice. Am J Cariol. 2007;100:25K-31K.

  77. Gonzalo N, Macava C. Absorbable stent: focus on clinical applications and benefits. Vasc Health Risk Manag. 2012;8:125-32.

  78. Delgadillo H, Vargas Alarcón G, Gómez Monterrosas O, et al. The MHC2TA gene polymorphisms are not associated with restenosis alter coronary stenting in Mexican patients. Arch Cardiol Mex. 2012; 82:208-13.

  79. Li JJ. Inflammation in coronary artery diseases. Chin Med J (Engl). 2011;124:3568-75.

  80. Sánchez Margalet V, Cubero JM, Martín Romero C, Cubero J, Cruz Fernández JM, Goberna R. Inflammatory response to coronary stent implantation in patients with unstable angina. Clin Chem Lab Med. 2002;40:769-74.

  81. Caixeta AM, Brito FS Jr, Costa MA, Serrano CV Jr, Petriz JL, Da Luz PL. Enhanced inflammatory response to coronary stenting marks the development of clinically relevant restenosis. Catheter Cardiovasc Interv. 2007;69:500-7.

  82. Kozinski M, Krzewina-Kowalska A, Kubica J, et al. Percutaneous coronary intervantion triggers a systemic inflammatory response in patients treated for in-stent restenosis—comparison with stable and unstable angina. Inflamm Res. 2005;54:187-93.

  83. Ozer N, Tangurek B, Firat F, et al. Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Heart Vessels. 2008;23:75-82.

  84. Wu Y, Zhang W, Liu W, Zhuo X, Zhao Z, Yuan Z. The double-faced metabolic and inflammatory effects of standard drug therapy in patients after percutaneous treatment with drug-eluting stent. Atherosclerosis. 2011;215:170-5.

  85. Taguchi I, Yoneda S, Abe S, et al. The late-phase inflammatory response after drug-eluting stent implantation. Heart Vessels. 2013. [Epub ahead of print]

  86. Monraats PS, Pires NM, Schepers A, et al. Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J. 2005;19:1998-2004.

  87. Koch W, Kastrali A, Böttinger C, Mehilli J, von Beckerath N, Schömig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis. 2001;159:137-44.

  88. Koch W, Tiroch K, von Beckerath N, Schömig A, Kastrati A. Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine. 2003;24:161-71.

  89. Völzke H, Grimm R, Robinson DM, et al. Candidate genetic markers and the risk of restenosis after coronary angioplasty. Clin Sci (Lond). 2004; 106:35-42.

  90. Zeng Z, Duan Z, Zhang T, et al. Association between tumor necrosis factor-α (TNF-α) promoter -308G/A and response to TNF-α blokers in rheumatoid arthritis: a meta-analysis. Mod Rheumatol. 2013;23:489-95.

  91. O´Rielly DD, Roslin NM, Beyene J, Pope A, Rahman P. TNF-alpha- 308G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J. 2009;9:161-7.

  92. Dixon WG, Watson KD, Lunt M, Hyrich LK. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor-therapy. Arthritis Rheum. 2007;56:2905-12

  93. Barnabe C, Martín BJ, Ghali WA. Sirtematic review and meta-analysis: anti-tumor necrosis factor-α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63:522-9.

  94. Ljung L, Simard JF, Jacobsson L, Rantapää-Dahlqvist S, Askling J. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum. 2012;64:42-52.

  95. Panteris V, Perdiou A, Tsirimpis V, Karamanolis DG. Acute coronary syndrome after infliximab therapy in a patient with Crohn´s disease. World J Gastroenterol. 2006;12:6235-8.



>Revistas >Gaceta Médica de México >Año2013, No. 5
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019